B8437
Anti-Biliverdin Reductase A antibody produced in rabbit
IgG fraction of antiserum, buffered aqueous solution
Synonyme(s) :
Anti-BLVR, Anti-BLVRA, Anti-BVR, Anti-BVRA
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
rabbit
Conjugué
unconjugated
Forme d'anticorps
IgG fraction of antiserum
Type de produit anticorps
primary antibodies
Clone
polyclonal
Forme
buffered aqueous solution
Poids mol.
antigen ~35 kDa
Espèces réactives
human
Technique(s)
immunoprecipitation (IP): 5-10 μL using human HeLa cell lysates
western blot: 1:250-1:500 using whole extracts of human HepG2 cells
Numéro d'accès UniProt
Conditions d'expédition
dry ice
Température de stockage
−20°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... BLVRA(644)
Catégories apparentées
Description générale
Biliverdin reductase A (BVRA) contains a domain that acts as a serine/ threonine/ tyrosine kinase and belongs to the insulin receptor substrate family. Whereas most tyrosine kinase activity is membrane-bound, BVR is a soluble protein. BVRA gene is mapped to human chromosome 7p13.
Spécificité
Anti-Biliverdin Reductase A recognizes human Biliverdin Reductase A.
Immunogène
human biliverdin reductase A recombinant protein.
Application
Anti-Biliverdin Reductase A antibody produced in rabbit may be used in western blotting and immunoprecipitation.
Actions biochimiques/physiologiques
Biliverdin reductase A (BVR, BLVRA) catalyzes the conversion of biliverdin to bilirubin in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) or nicotinamide adenine dinucleotide (NADH). Biliverdin reductase A is also considered as a major physiologic cytoprotectant and may have other protective properties in disease states. It has been shown to suppress experimental autoimmune encephalomyelitis in rats. The depletion of the enzyme leads to the accumulation of cellular oxidants and augmented cell death. Mutation in the BVRA gene is implicated in hyperbiliverdinaemia or green jaundice.
Forme physique
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Stockage et stabilité
Store at -20 °C. For continuous use, the product may be stored at 2-8 °C for up to one month.For extended storage, freeze at -20 °C in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution bycentrifugation before use. Working dilution samples should be discard if not used within 12 hours.
Clause de non-responsabilité
Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Mats Gåfvels et al.
Liver international : official journal of the International Association for the Study of the Liver, 29(7), 1116-1124 (2009-07-08)
Hyperbiliverdinaemia is a poorly defined clinical sign that has been infrequently reported in cases of liver cirrhosis or liver carcinoma, usually indicating a poor long-term prognosis. To clarify the pathogenesis of hyperbiliverdinaemia in an extended case report. A 64-year-old man
Flavia Agata Cimini et al.
Biochimica et biophysica acta. Molecular basis of disease, 1865(6), 1490-1501 (2019-03-04)
Biliverdin reductase-A (BVR-A) is a serine/threonine/tyrosine kinase involved in the regulation of insulin signaling. In vitro studies have demonstrated that BVR-A is a substrate of the insulin receptor and regulates IRS1 by avoiding its aberrant activation, and in animal model
Urszula M Florczyk et al.
Pharmacological reports : PR, 60(1), 38-48 (2008-02-16)
Biliverdin reductase (BVR) was known for a long time solely as an enzyme converting biliverdin to bilirubin, the major physiological antioxidant. Recent years revealed unique features of this protein which are not related to its reductase activity. The most intriguing
Nidhi Sharma et al.
Neurobiology of disease, 125, 176-189 (2019-02-10)
Hyper-active GSK-3β favors Tau phosphorylation during the progression of Alzheimer's disease (AD). Akt is one of the main kinases inhibiting GSK-3β and its activation occurs in response to neurotoxic stimuli including, i.e., oxidative stress. Biliverdin reductase-A (BVR-A) is a scaffold
Damian Klóska et al.
Archives of biochemistry and biophysics, 678, 108182-108182 (2019-11-11)
Endothelial dysfunction accompanied by the loss of endothelial cell phenotype plays an essential role in cardiovascular diseases. Here, we report that knockdown of biliverdin reductase (BVR), the enzyme of the heme degradation pathway converting biliverdin to bilirubin, shifts endothelial phenotype
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique